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Objective: Research has suggested open-label placebos are effective, however, there is a lack of 
research comparing the effectiveness of an open-label placebo (OLP) with a deceptive placebo (DP), 
although one study did find an OLP and DP were equally as effective for reducing pain. Furthermore, 
there is a gap within the literature investigating the influence of personality within OLP responding. 
This study aimed to compare the effectiveness of an OLP to a DP and investigated the role of 
personality within OLP analgesia.  
Method: 75 participants were allocated to one of three groups; OLP (n = 25), DP (n = 26) and no-
treatment (NT; n = 24). All participants completed a baseline cold pressor test (CPT) and measures of 
pain tolerance and pain intensity. Participants in the OLP group were informed they were receiving a 
placebo and participants in the DP group were informed they were receiving a painkiller. Those in the 
OLP and DP groups then received a placebo nasal spray, with the NT group receiving no placebo. All 
participants then completed a second CPT and the pain measures. Several personality-related 
variables were also measured. 
Results:  A one-way ANCOVA revealed no significant differences between groups for pain tolerance, 
F(2, 71) = 1.903, p = .157. However, significant differences were revealed between groups for self-
reported pain intensity, F(2, 71) = 4.838, p = .011, η2 = .120. Planned contrasts revealed that receiving 
an OLP and a DP significantly decreased pain intensity compared to the NT group, with no significant 
differences between the effectiveness of the OLP and the DP. Exploratory analysis, using moderated 
regression analysis, revealed fear of minor pain was positively associated with placebo analgesia 
within the OLP group. Fear of medical pain was positively associated with pain intensity for those in 
the OLP group, however, there was a negative association for those in the DP group. There was a 
positive association between pain intensity and agreeableness for those in the DP group, however, a 
negative association for those in the OLP group.   
Conclusion: An OLP and a DP were both effective for reducing subjective pain intensity, although there 
were no significant differences between OLP and DP effectiveness. This suggests the use of deception 
within placebo analgesia should be questioned with healthy participants, as placebos given openly 
remained as effective as placebos given deceptively. This was also the first study to highlight that 
agreeableness, fear of minor pain, and fear of medical pain moderated OLP analgesia in a differing 
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The use of placebos is well documented within medical practice (Charlesworth et al. 2017); however, 
placebos have been argued to be unethical, given medical professionals are required to deceive 
patients about the true nature of a placebo (Petkovic et al., 2015; Fässler, Meissner, Schneider, & 
Linde, 2010). Despite the argument, it was reported that, within the UK, 12% of General Practitioners 
(GPs) used a pure placebo (placebo with no pharmacologically active ingredients such as a sugar pill) 
within their career. It was also found that 97% of GPs used an impure placebo (a substance or 
intervention with some known clinical or physical value, however lacking specific therapeutic effects 
such as off-label uses of potentially effective therapies) at least once within their career (Howick et al. 
2013). Although the use of placebos is well documented, the level of effectiveness of placebos is 
inconsistent within research (Howe, Goyer, and Crum 2017). Furthermore, suggestions have been 
made that the placebo effect is more effective in patients compared to healthy individuals (Forsberg, 
Martinussen, and Flaten 2017), suggesting placebo research using healthy participants may 
underestimate the effectiveness of placebos when compared to a clinical sample.  
 
Placebos have been found to be effective for reducing pain, otherwise known as placebo analgesia, 
within healthy participants (Bąbel et al. 2017; Geers et al. 2015; Rosén et al. 2017) and within clinical 
samples with those suffering from lower back pain and chronic pain  (Charron, Rainville, and Marchand 
2006; Müller et al. 2016). In addition, placebos have also been used to reduce symptoms for various 
other medical conditions, including psychological disorders such as depression (Walsh et al. 2002) and 
schizophrenia (Kinon, Potts, and Watson 2011). A meta-analysis has also indicated that placebo 
surgeries, for conditions such as severe obesity and gastro-oesophageal reflux, relieve symptoms in 
75% of cases, with there being no significant difference between the effectiveness of a placebo surgery 
and a genuine surgery within over half of the cases analysed (Wartolowska et al. 2014). Furthermore, 
it is often suggested that placebo effects are only relevant with subjective outcomes, such as patient-
reported pain (Breidert and Hofbauer 2009; Hróbjartsson and Gøtzsche 2001; Kaptchuk and Miller 
2015), usually only relieving symptoms and side effects, opposed to curing illnesses (Kaptchuk and 
Miller 2015). However, there is some evidence that placebo effects can influence objective outcomes, 
such as decreasing a rash size from a histamine skin prick test (Howe et al. 2017) and influencing 





Until recently, it was believed that for placebo effects to occur, deception was necessary (Kaptchuk, 
2018; Leibowitz, Hardebeck, Goyer, & Crum, 2019). In other words, for an individual to experience a 
placebo effect, they were required to believe that the placebo they received was a genuine drug with 
active ingredients. However, given the long-standing belief that placebos require deception,  the use 
of placebos within medical practice has been argued to be unethical (Charlesworth et al. 2017; Colloca 
and Howick 2018). Thus, Kaptchuk et al. (2010) suggested that finding effective ways of harnessing 
the placebo effect without deception should be of high priority. In recent years, research has 
questioned whether deception is a necessary component within the placebo effect, by prescribing 
placebos without deception, referred to as an open-label placebo (OLP). Thus, an OLP is a placebo 
prescribed where a patient has the knowledge and understanding that it is a placebo containing no 
active ingredients.   
 
1.1. Open-label placebos 
Open-label placebos have been documented to elicit placebo analgesia within clinical samples 
suffering from chronic lower back pain and episodic migraine attacks (Carvalho et al., 2016; Kam-
Hansen et al., 2014). OLP effects have also been demonstrated and have shown some effectiveness 
when reducing symptoms for various other medical conditions; Attention Deficit Hyperactivity 
Disorder (ADHD; Sandler & Bodfish, 2008), Irritable Bowel Syndrome (IBS; Kaptchuk et al., 2010), 
cancer-related fatigue (Hoenemeyer et al. 2018; Zhou et al. 2019) depression (Kelley et al. 2012), and 
allergic rhinitis (Schaefer, Harke, and Denke 2016; Schaefer, Sahin, and Berstecher 2018).  
 
Placebos without deception have mostly only focussed on clinical samples, however, there is a limited 
amount of research with healthy participants, some of which is inconsistent (Barnes et al. 2019; El 
Brihi, Horne, and Faasse 2019; Locher et al. 2017; Mathur et al. 2018; Meeuwis et al. 2018). Some 
studies using healthy participants have found positive OLP effects such as improving wellbeing and 
sleep quality, and reducing the level of itch individuals expected after receiving a histamine 
iontophoresis (El Brihi et al. 2019; Meeuwis et al. 2018). However, Barnes et al. (2019) found that an 
OLP was not useful for reducing experimentally induced nausea using brain stimulation as a placebo. 
It must be said, however, that these studies investigated different effects and utilised different 
placebos with El Brihi et al. (2019) using placebo pills and Meeuwis et al. (2018) using verbal 
suggestions. A further OLP effect was highlighted by Locher et al. (2017), whereby receiving a placebo 




the other hand, it was found that there were no OLP effects within objective pain tolerance (Locher 
et al. 2017). This is also in line with Mathur et al. (2018) whereby it was demonstrated that an OLP did 
not influence wound healing, an objective outcome. 
 
A limitation within the current OLP literature is that the ‘control’ group used in the above studies is 
not consistent, with some studies using a no-treatment group (Kaptchuk et al. 2010; Sandler and 
Bodfish 2008), and others using a ‘treatment as usual’ group as the comparison group (Carvalho et al. 
2016). This, however, does raise the question whether the full extent of an OLP effect can be 
highlighted if a control group continues to experience other treatment. In addition, the majority of 
OLP studies only compare an OLP with a control group, without being compared to a deceptive 
placebo (DP) group, a group whereby participants believe the placebo to be an active drug. This, 
therefore, suggests that research comparing an OLP with a control group only has the potential of 
suggesting an OLP is effective compared to those who have not received any placebo. However, 
without a DP group being included in the same studies, it can only be possible to confirm that an OLP 
is effective to some extent, without knowing how effective it is compared to a DP.  
 
Although there is a lack of research comparing the effectiveness of an OLP with a DP, there are a small 
number of studies which have compared their effectiveness (Barnes et al., 2019; Locher et al., 2017). 
Locher et al. (2017) compared two OLP groups, one with and one without a plausible rationale, a DP 
group, and a no-treatment group within a laboratory study measuring objective pain tolerance, and 
subjective pain intensity and unpleasantness ratings within a heat pain test. It was found that there 
were no group differences for objective pain tolerance, with all placebo groups showing no placebo 
analgesia. However, regarding subjective ratings of pain, the OLP group with a rationale to increase 
expectation of pain relief and the DP group, did not significantly differ in terms of effectiveness, with 
an OLP group and DP group experiencing less pain than those in the OLP group without a rationale to 
increase expectation. This suggests that, on the condition that an OLP is given with a plausible 
rationale consisting of several statements to increase expectancy of pain relief from a placebo, it 
remains equally as effective as a DP; questioning the relevance of deception within placebo analgesia.  
A further study compared an OLP and DP within healthy participants to investigate whether it was 
possible to reduce experimentally induced nausea (Barnes et al. 2019). Two experiments were 
conducted utilising two different methods of modelling nausea and two different types of placebos. It 
was found that when using Galvanic Vestibular Stimulation to model nausea and a peppermint vapour 




Virtual Reality to induce nausea and brain stimulation as a placebo, there were significant placebo 
effects for the DP group, however, not for the OLP group. Although Barnes et al. (2019) contradicts 
the findings of Locher et al. (2017) it is important to understand that both studies focus on different 
outcomes, however, Barnes et al. (2019) also suggested that other characteristics are likely to be 
involved with the likelihood of responding to a placebo such as the type of placebo used.  
 
1.2. Expectancy and conditioning theories  
Two dominant theories which seek to explain the placebo effect are expectancy and classical 
conditioning (Stewart-Williams and Podd 2004). Expectancy theory refers to the concept that 
individuals experience a relief in symptoms because they expect it, with the expectation of relief 
creating a placebo effect (Stewart-Williams and Podd 2004). Conditioning has also been argued to 
explain the placebo effect, for example, taking the classical conditioning concept of repeatedly pairing 
a neutral stimuli (NS) with an unconditioned stimuli (US, which creates an unconditioned response, 
UR), the NS becomes conditioned to create the same response as the US, thus, becoming a 
conditioned stimuli (CS) to create a conditioned response (CR). To explain this in terms of the placebo 
effect, a drug may be an US which leads to an UR, for example pain relief. By administering a NS such 
as a pill case, containing an US (such as a painkiller) which creates an UR (such as pain relief), the 
painkiller is repeatedly paired with the method of administration of the drug; in this case a pill case. 
Through repeated pairing of the NS and the US, the pill case could become associated with pain relief, 
without the painkilling ingredient being inside the pill case. Thus, a placebo is the CS and the placebo 
effect is a CR (Stewart-Williams and Podd 2004).   
 
Although expectancy theory has been suggested to be a key theory, Kaptchuk (2018) has suggested 
that it assumes recipients have positive experiences with treatment, however, he suggested that 
patients, in fact, do not hold positive expectations towards treatments. Furthermore, clinical evidence 
is inconsistent for the role of expectancy within the placebo effect (Kaptchuk 2018).  When specifically 
investigating the role of expectancy for the OLP, research is also inconsistent as it has previously been 
found that expectations did not influence the efficacy of an OLP in one study (Schaefer et al. 2018). 
However, it has also been found that, by raising expectation through a positive rationale, expectation 
does increase the effectiveness of an OLP (Locher et al. 2017). Classical conditioning also relies on 
positive previous experience, otherwise positive placebo outcomes would not be experienced. 




positively to previous medical interventions, Kaptchuk (2018) has claimed conditioning is unlikely to 
be major factor when explaining the OLP.  
 
With regards to this study, we assume that expectation may hold greater merit when explaining OLP 
analgesia within a healthy sample for the following reasons. The study which is most similar to this 
current study in terms of methodology and aims, Locher et al. (2017), found that when an OLP was 
given with a rationale to increase expectation of pain relief, it was more effective than an OLP given 
without a rationale. This suggested that the role of expectation may hold importance within OLP 
analgesia and, therefore, this current study takes into consideration the findings and the potential 
usefulness of the role of expectation when increasing the effectiveness of an OLP. When taking into 
account the role conditioning may have within OLP studies containing healthy participants such as this 
study, if conditioning were to be the underlying mechanism explaining an OLP, it would be assumed 
that all participants who experiences a placebo effect would have previous experience with the 
placebo in a genuine medication form. For example, given Locher et al. (2017) used a placebo analgesic 
cream, for conditioning to be an underlying mechanism explaining how a placebo cream given openly 
reduced pain, it would have to be the case for all participants who experienced a reduction in pain to 
have previously experienced pain relief from a genuine analgesic cream. It is, however, unlikely that 
all participants had previous exposure to an analgesic cream, and therefore unlikely that conditioning 
was an underlying mechanism. Thus, given expectancy has been demonstrated to be somewhat useful 
when increasing the effectiveness of an OLP, and it is unlikely for all participants to have had previous 
exposure with the placebo form as a genuine medication, this study assumes that expectancy is more 
likely to play a greater role within placebo analgesia. Finally, although conditioning and expectancy 
theories appear to be most dominant within placebo literature, it could be the case that there are 
further mechanisms, or an interaction of mechanisms, which lead to OLP effectiveness.  
 
1.3. Personality and deceptive placebo responding 
Research has also indicated that personality may have some influence on placebo responding, 
although the role of personality within placebo responding presents itself as ambiguous, and research 







Optimism appears to be one of the most consistent predictors of placebo responding (Geers 
et al., 2005, 2007, 2010; Locher et al., 2019; Morton et al., 2009), although there are also 
inconsistencies within the literature highlighting that optimism does not influence placebo 
responding (Peciña et al. 2013; Vachon-Presseau et al. 2018).  
 
When understanding the reasons why optimism may predict placebo responding, Maltby et 
al. (2010) suggested that those who are more optimistic usually expect positive outcomes, 
meaning optimists are more likely to work towards achieving goals and not giving up in the 
process. On the contrary, Maltby et al. (2010) stated the opposite for pessimists, with 
pessimists more likely to expect negative outcomes, meaning they are more likely to give up 
on achieving their goals. When applying this to the placebo effect, optimists may be more 
likely to expect a positive outcome from a placebo, such as pain relief or a reduction in 
symptoms, and in the process, they do end up experiencing greater benefits from a placebo. 
Pessimists, however, may be less likely to experience a placebo effect as they may not expect 
the placebo to be effective and, consequently, they may not experience the benefit from the 
placebo that a more positive thinker may experience. Thus, it is possible to speculate that the 
role expectancy plays within the placebo effect may be similar to the role optimism plays as 
optimism and expectancy appear to be closely related mechanisms.  
 
1.3.2. Big 5 
Although optimism appears to be the most consistent personality-related predictor of placebo 
responding (Locher et al. 2019), elements of the Big 5 have also been suggested to predict 
placebo responding; extraversion (Kelley et al. 2009), agreeableness (Kelley et al. 2009; Peciña 
et al. 2013), openness (Kelley et al. 2009; Vachon-Presseau et al. 2018), and neuroticism has 
been found to be a negative predictor of placebo responding (Peciña et al. 2013).  
 
When understanding the role agreeableness may play within placebo responding, it has been 
stated that those who score higher on agreeableness are more trusting, however, those who 
score lower are usually more sceptical (Maltby et al., 2010). Thus, this suggests that those who 




score lower on agreeableness may be more sceptical about whether the placebo will be 
effective, potentially decreasing its effectiveness. Furthermore, Quilty et al. (cited in Peciña et 
al., 2013) stated that those who score high on agreeableness are likely to have a stronger 
patient-doctor relationship and, therefore, are more likely to engage within therapy. 
 
Extraversion was revealed to be the most robust predictor of placebo responding within the 
findings of Kelly et al. (2009), suggesting that those who are sociable, assertive and optimistic 
are more likely to experience a placebo effect (Maltby et al., 2010). Furthermore, with 
previous research finding neuroticism to be a negative predictor of placebo responding 
(Peciña et al., 2013), this suggests those who are calmer and more emotionally adjusted are 
more likely to experience a placebo effect (Maltby et al., 2010). Thus, those who are 
emotionally unstable are less likely to experience a placebo effect. Finally, with openness also 
being a predictor of placebo responding, it is highly likely that the explanation is as follows; 
those who are more open to new experiences are also more open to a new form of medication 
and, therefore, are more likely to experience the effects of a placebo. 
 
1.3.3. Behavioural activation systems  
Two elements from the BIS/BAS scales (Carver & White, 1994) have also been found to be 
associated with placebo responding; BAS drive and BAS fun seeking (Darragh, Booth, and 
Consedine, 2014; Schweinhardt et al., 2009), however, studies have contradicted each other. 
When research was conducted on the placebo effect within pain (Schweinhardt et al., 2009), 
BAS drive and BAS fun seeking were identified to positively predict placebo responding, 
however, in a non-pain context the same traits were negatively associated with placebo 
responding (Darragh et al., 2014). It has, therefore, been suggested that the influence of 
personality on placebo responding, specifically BAS drive and BAS fun-seeking, may differ 
within pain and non-pain contexts (Darragh et al. 2014). Furthermore, given research has 
highlighted this inconsistency and the influence of behavioural drive and fun-seeking is not 
fully established, further research should be conducted to further uncover the relationships 






1.3.4. Fear of pain  
Fear of pain has also been identified to reduce placebo responding with both dispositional 
fear (Lyby, Aslaksen, and Flaten, 2010, 2011) and induced fear (Lyby et al., 2012). More 
specifically, those who fear severe pain are less likely to respond to a placebo (Lyby et al., 
2010). Thus, those who fear pain are less likely to experience a placebo effect. When seeking 
an explanation for this, Lyby et al. (2010) found that fear of pain was also related to stress 
during pain and in the anticipation of pain, suggesting those who are more stressed are more 
likely to fear pain and, consequently, less likely to experience a placebo effect.  
 
1.3.5. Interactional approach 
Although there are various examples where personality has been found to influence the 
likelihood of responding to a placebo, it has been suggested that, rather than there being a 
specific placebo personality, placebo responding may be explained by an interaction between 
dispositional and contextual factors (Darragh et al., 2014). Darragh, Booth, and Consedine 
(2015) referred to this as a transactional model.  To further explain this, it has been suggested 
that dispositional factors, such as personality, interact with situational factors, such as the 
environment (Jakšić, Aukst-Margetić, & Jakovljević, 2013), with the strength and direction of 
the relationship between personality and placebo responsiveness being affected by 
situational variables. For example, the role of behavioural drive and fun-seeking may vary 
between contexts such as within pain contexts and non-pain contexts (Darragh et al., 2014; 
Schweinhardt et al., 2009). 
 
Another example of an interaction is where pessimists were more likely than optimists to 
experience negative placebo effects, following a negative expectation stating a placebo would 
make them feel unpleasant (Geers et al., 2005). Furthermore, Geers et al. (2007) found that 
optimistic people were more likely to experience a placebo effect when given a positive 
placebo expectation. Thus, this suggests that, although optimism and pessimism play some 
role in predicting placebo responding, this is only relevant within particular contexts; such as 
receiving a positive or negative expectation. Research has also indicated an interactional 
approach with extraversion and agreeableness, with those who scored higher on extraversion 
and agreeableness responding more effectively with an empathic clinician (Kelley et al. 2009). 




contextual factor of the characteristics of the clinician. Through understanding an individual’s 
personality and the most suitable context it, therefore, may be possible to match individuals 
to placebo treatments which are most likely to be effective (Darragh et al. 2015). 
 
1.4. Personality and open-label placebo responding  
Although personality has been investigated in many studies with the DP, to date, there has been only 
one study which investigated personality with regards to the OLP (Locher et al. 2019). Locher et al. 
(2019) conducted a study investigating whether personality predicts OLP responding with healthy 
participants experiencing experimentally induced heat pain. Several personality-related variables 
were measured including; optimism, openness to experience, locus of control, and positive attitudes 
towards alternative and complementary medicine. Although optimism predicted DP responding, it 
was found that optimism did not predict OLP responding. Moreover, no other personality-related 
variables predicted OLP responding, suggesting that there is no typical ‘OLP responder’ personality. 
However, although this was the only study to research personality and OLP responding, there are 
several other personality-related variables suggested to predict DP responding in the DP literature 
which Locher et al. (2019) did not address. This, therefore, suggests that there may be personality 
traits predicting DP responding which may also predict OLP responding, which have not yet been 
researched. Thus, it is important to conduct further studies into the role of personality within OLP 
responding.  
 
1.5. Rationale  
Although OLPs have been found to be effective within some instances, there is a limited amount of 
research comparing OLP’s with DPs. Furthermore, of the two known studies which have compared 
OLPs and DPs, Locher et al. (2017) and Barnes et al. (2019) found conflicting findings, although both 
studies were investigating unrelated outcomes. With a very limited amount of research comparing 
placebos given openly and deceptively and inconsistencies present in that pre-existing literature, it is 
important to conduct further research to understand the role which deception does play within the 
placebo effect. Through conducting research of this kind and understanding the relevance of 
deception within the placebo effect, only then can the potential of the use of OLPs within the real 
world be explored. It is, therefore, important to understand how the effectiveness of an OLP and DP 
compare to understand whether placebos can be given in a more ethical way, without deception, 




Given the lack of research comparing the role of personality within OLP responding, it is important 
that further research is conducted to both understand whether personality does influence OLP 
responding and whether personality influences OLP and DP responding in the same way. Given there 
is some research investigating the role of personality within DP responding, although limited, it 
suggests that personality may have some influence over the likelihood of responding to a placebo and, 
therefore, it is important to know whether the same personality traits influence OLP responding as 
this could suggest similar mechanisms may explain OLP and DP responding. Furthermore, if different 
personality-related variables were found to predict OLP and DP responding, this could have a 
potentially useful implication of using personality testing to match an individual to the best form of 
treatment, a placebo given openly or a placebo given deceptively. Furthermore, given little is known 
about the mechanisms explaining the OLP effect, understanding the role personality plays within OLP 
responding may be useful for understanding how and why the OLP could be effective.  
 
Given this research was exploratory and there is very little research understanding the role of 
personality within OLP responding, it was important to measure personality traits which have been 
found to be effective for predicting DP responding as a basis as to what personality traits may also 
influence OLP responding. Furthermore, given questionnaires measuring personality traits which have 
been found to predict placebo responding also measure other personality traits, and this research was 
exploratory, the full questionnaires were given to participants. Thus, this meant that personality traits 
which have been suggested to influence DP responding were measured within this study, however, 













1.6. This study 
The current study seeks to investigate two key questions. Firstly, are open-label placebos effective 
compared to a no-placebo control group within a cold-pressor test and, if so, how does their 
effectiveness compare to deceptive placebos? Secondly, do personality-related variables influence 
open-label placebos and, if so, is the relationship the same as with deceptive placebos? Therefore, we 
firstly hypothesised that OLP and DP groups will experience enhanced placebo analgesia (increased 
pain tolerance and decreased pain intensity) within a cold-pressor test compared to a no-treatment 
(NT) control group. Secondly, we investigated whether there were any differences between the 
effectiveness of an OLP and a DP within placebo analgesia. Finally, given there is little research 
investigating personality in relation to the OLP, exploratory analysis was performed to investigate 


































Using an opportunity sampling method, 104 participants were recruited from the University of 
Huddersfield’s Psychology department. However, several participants were excluded for reaching or 
being very close to the ceiling immersion time of 180 seconds within the baseline cold pressor test 
(CPT). See Appendix 1 for the histogram demonstrating the ceiling effect. As demonstrated by the 
histogram, there is a slightly skewed normal distribution between 0 seconds and 109 seconds, within 
the baseline CPT immersion times. However, no participants immersed their hands for a time period 
between 109 seconds and 162 seconds, with 4 participants immersing their hands for a time period 
between 162 and 178 seconds, and 25 participants immersing their hand for the full-time period 
permitted. This, therefore, meant that by removing those who were affected by the ceiling time from 
data analysis, there was a relatively normal distribution, although slightly skewed. More importantly, 
given an immersion time of 180 seconds meant that participants pain tolerance was higher than we 
were able to test, it was not possible to indicate whether a placebo effect had taken place or not when 
comparing the baseline CPT to the post-treatment CPT.  
 
Therefore, only 75 participants were included within data analysis. 87% of participants were female 
(n = 65) and 13% were male (n = 10), with an age ranging between 18 and 54 (mean = 21.05, SD = 
5.042). Participants participated in one of three groups; OLP (n = 25), DP (n = 26) and NT (n = 24). 
Participants were randomised into the OLP and NT group, however, given recruitment for the DP 
occurred at a later date, participants were not randomly assigned to this group; thus, any participants 
who volunteered to participate in the DP condition believed they were taking part in a study which 
investigated individual differences within painkiller responding. All groups consisted of a greater 
number of females; OLP group (76%), DP group (96%) and NT group (87.5%) and all other 
characteristics remained similar across all three groups.  
 
2.2. Design 
A 3 x 2 mixed factorial design was used. The between-subjects factor was experimental condition 
which had three groups; OLP, DP and the NT. The within-subjects factor was CPT trial with two levels; 
baseline CPT and post-treatment CPT. There were two dependent variables measuring pain 
perception; objective pain tolerance and subjective pain intensity. Objective pain tolerance was the 




scale ranging from 0 to 100, with 0 representing no pain and 100 representing the most intense pain 
imaginable. Various personality-related variables were also measured throughout this study. 
 
As previous research has demonstrated there are large individual differences in pain perception 
(Rutchick and Slepian 2013), it was important to measure participant’s pain perception before being 
given a placebo; ensuring any differences between the three groups were because of the 
administration of a placebo and not genuine differences in participant’s pain perception.  Thus, a pre-
test post-test design was utilised with participants completing a baseline CPT before being given any 
stimuli which may influence pain perception. Furthermore, consumption of painkillers before 
participating in pain research may influence pain perception, suggesting it was important to screen 
participants for recent painkiller use to ensure there were no differences within painkiller usage 
between groups (Rutchick and Slepian 2013). Moreover, participants were screened for medical 
conditions which may influence their pain perception. Any participants who suffered from any listed 
medical conditions did not participate; acute or chronic pain, cardiovascular problems, arthritis, 
diabetes, fibromyalgia, Reynaud’s Disease, or if participants were allergic to sodium chloride. 
 
2.3. Materials and Apparatus 
Participant Booklet 
Participants were given a paper booklet which consisted of an information sheet, consent form and 
debrief sheet. In addition, the booklet included questions for a reading comprehension task given in a 
separate booklet and a placebo information sheet or painkiller information sheet was included for 
those in the OLP and DP groups.  
 
Online Materials 
Qualtrics, an online survey platform, was used to collect data and inform participants about their tasks 
throughout the study and was displayed on a computer screen within the laboratory. Participants 
followed instructions on the computer screen throughout the research process with limited 
researcher-participant interaction. Qualtrics was also used to collect responses to all psychometric 
measures within this study. Qualtrics follows the US, EU and Swiss Safe Harbor Framework regarding 






Basic demographic information was collected from each participant, including; gender, age and 
marital status. Furthermore, at the end of this questionnaire, participants were screened for the use 
of painkillers within the last four hours. Participants were informed on all recruitment materials that 
they should not take painkillers within the 4 hours prior to them taking part in this research to control 
for the influence of painkillers on participant’s pain perception (Rutchick and Slepian 2013).  
 
Information provided to the OLP condition 
Participants in the OLP group were given a placebo information sheet. The information sheet included 
basic instructions to familiarise participants with the method of administrating the placebo. 
Furthermore, this information sheet included several statements with the purpose of increasing the 
expectation of pain relief from administering a placebo (Locher et al. 2017).  Firstly, participants were 
informed that the nasal spray is inactive and does not contain any painkilling properties. Participants 
were also informed that, although they are administering a placebo, they may still experience pain 
relief, given previous research has demonstrated that placebos can reduce symptoms and reduce pain 
when participants have an understanding that they have administered a placebo. Moreover, the 
placebo information sheet informed participants that having a positive attitude towards the placebo 
can improve its effectiveness, however, a positive attitude is not necessary. Research has suggested 
that raising expectation of pain relief from a placebo is a useful way of increasing the effectiveness of 
an OLP (Locher et al., 2017). This study replicated two key pieces of information from Locher et al. 
(2017) to increase expectation of pain relief regarding the effectiveness of open-label placebos, and 
that a positive attitude can be helpful, however, not necessary. See Appendix 2.  
 
Information provided to the DP condition 
Participants in the DP condition were given a painkiller information sheet. Alike to the placebo 
information sheet, information was given explaining how to administer the nasal spray. The 
information followed a similar format to that used in previous research (Locher et al., 2017). 
Participants were informed that they were receiving an analgesic nasal spray, containing Lidocaine, 
the main ingredient used in Stilex (a painkiller used in Switzerland). The information sheet stated that 
Lidocaine provides pain relief for a short period of time, providing relief from medical procedures and 
for chronic pain. It was also suggested that the effectiveness of the painkiller had been tested in 




to induce an analgesic effect. Although this explanation was inspired by Locher et al. (2017), there 
have been some adaptations including changing the description to suit a nasal spray, as opposed to 
an analgesic cream. See Appendix 3. 
 
Big Five Inventory- 2  (BFI-2; Soto & John, 2017) 
The BFI-2 is a developed version of the Big Five Inventory (BFI) measuring extraversion, agreeableness, 
conscientiousness, negative emotionality and open-mindedness. It includes 60 items rated on a Likert 
scale; disagree strongly, disagree a little, neutral; no opinion, agree a little, and agree strongly. Each 
personality trait is measured by 12 items. Each personality trait had a score ranging from 12 to 60, 
with higher scores representing more demonstration of the personality trait. The BFI-2 is a reliable 
and valid measure of said personality traits, with the five measured traits correlating with other 
established personality measures; BFI, Big Five Aspect Scales (DeYoung, Quilty, and Peterson 2007), 
Big Five Mini-Markers (Saucier 1994), NEO Five-Factor Inventory (NEO-FFI; McCrae & Costa, cited in 
Soto & John, 2017) and NEO Personality Inventory-Revised (NEO PI-R; McCrae & Costa, cited in Soto 
& John, 2017). Cronbach’s alpha for this sample is as follows; extraversion (α = .84), agreeableness (α 
= .71), conscientiousness (α = .82), negative emotionality (α = .91) and open-mindedness (α = .84).  
 
Fear of Pain Questionnaire-III (FPQ-III; McNeil & Rainwater, 1998) 
The FPQ-III is a 30-item questionnaire which measures the level of fear or anxiety felt towards various 
painful stimuli. Answers are recorded on a 5-point Likert scale; not at all, a little, a fair amount, very 
much and extreme. The possible range of scores for fear of pain is between 30 and 150, with higher 
scores representing more fear of pain and can be used with both a clinical and healthy population. 
There are three subscales within the FPQ-III, each with 10 items; fear of minor pain, fear of severe 
pain and fear of medical pain. The range of scores for each subscale is between 10 and 50. The FPQ-
III has good construct, concurrent and ecological validity (Hursey & Jacks, cited in McNeil & Rainwater, 
1998). There is good internal consistency within this sample; fear of pain (α = .91), fear of severe pain 







Behavioural inhibition system/Behavioural activation system scales (BIS/BAS scales; Carver & White, 
1994) 
The BIS/BAS scales are a 24-item questionnaire measuring 4 sub-scales. One subscale measures the 
BIS (7 items) with the other three subscales relating to the BAS; BAS drive (4 items), BAS reward 
responsiveness (4 items) and BAS fun seeking (5 items). Answers are given on a four-point Likert scale; 
very true for me, somewhat true for me, somewhat false for me, very false for me. The range of scores 
for the BIS is between 7 and 28. For BAS drive and BAS reward responsiveness, the range of scores is 
between 4 and 16, and between 5 and 20 for BAS fun-seeking. The BIS/BAS scales have good validity 
and test-retest correlations demonstrate a reasonable level of reliability (Carver et al. 1994). 
Cronbach’s alpha within this sample is as follows; BAS drive (α = .69), BAS fun seeking (α = .68), BAS 
reward responsiveness (α = .62) and BIS (α = .86). 
 
Life orientation test-revised (LOT-R; Scheier, Carver, & Bridges, 1994) 
The LOT-R is a 10-item questionnaire, measuring dispositional optimism, with three items measuring 
optimism, three items measuring pessimism and four items performing the role of filler items. All 
items are rated on a five-point Likert scale; I agree a lot, I agree a little, I neither agree nor disagree, I 
disagree a little and I disagree a lot. The range of scores within the LOT-R is 0 to 24. The LOT-R has a 
good level of test-retest reliability, internal consistency and validity (Scheier et al. 1994). There was 
good internal consistency within the sample used in this study (α = .79).  
 
Saline nasal spray  
The placebo used in this study was the Boots Pharmaceuticals Saline Nasal Spray (15ml) with the 
advertised medical relief of nasal congestion for babies, infants and children. The nasal spray 
contained no active or painkilling ingredients. The ingredients are as follows; an isotonic buffered, 
aqueous saline solution containing sodium chloride 0.75%, 0.01% EDTA, 0.0002% PHMB. Nasal sprays 
were disposed of after each use. There are no known side effects of this product, however, online 
documentation suggests that, although very rare, individuals should seek urgent medical advice if they 







Cold Pressor Test (CPT) 
The cold-water bath used within this study was the Lab Companion, Jeio Tech refrigerating bath 
circulator, maintained at three degrees Celsius. The maximum immersion time for all participants was 
180 seconds (Rutchick & Slepian, 2013). The CPT is a method of experimentally induced pain and 
mimics the pain experienced within chronic conditions effectively and is considered to be safe (von 
Baeyer, Piira, Chambers, Trapanotto, & Zeltzer, 2005; Mitchell, MacDonald, & Brodie, 2004). The 
circulatory nature of this apparatus ensured that heat cannot build up around the hand, and the 
temperature remains a constant three degrees Celsius throughout the test (von Baeyer et al. 2005). 
Moreover, the apparatus had a digital thermometer to ensure the water was maintained at the same 
temperature for all participants, ensuring equivalence of pain stimulus.  
 
Pain perception measures 
Two measurements were recorded of pain perception during this research; objective pain tolerance 
and subjective pain intensity. The time period, measured in seconds, in which participants kept their 
hand immersed in the cold-water bath was the measurement of pain tolerance in this study. 
Participants were informed that, when they cannot withstand any pain they may feel, they should 
remove their hand (Rutchick and Slepian 2013). Thus, immersion time is the result of the time period 
in which participants can tolerate the pain and when participants do remove their hand from the water 
bath, this highlights that they can no longer tolerate the pain. Pain Intensity at the most painful 
moment during the CPT was measured using a digital visual analogue scale (VAS) between 0 and 100. 
0 represented no pain sensation and 100 represented the most intense pain sensation imaginable 
(Locher et al. 2017). Participants were asked to move a digital slider to the most accurate 
representation of their pain intensity, with the chosen number rating being clearly indicated on the 
computer screen. VAS’s have been found to have good validity and excellent reliability (de Boer et al. 
2004). 
 
Reading Comprehension Task (k5 Learning, 2014) 
A reading comprehension task was given to participants as a filler task between the two cold pressor 
tests. This was included in order to minimise pain sensitisation effects for the second cold pressor task. 
The reading comprehension task included four reading tasks of a low level to ensure participants did 
not find them too challenging. Each text had its own set of questions included in the participant 




are clouds?’, ‘Mount Rushmore; Birth, expansion, preservation, and development’, ‘the sun and the 




The School ethics committee were presented with all participant materials and procedures before 
granting permission to conduct this study. Participant materials included information sheets providing 
sufficient information for participants to give informed consent to take part in the study, consent 
forms and debrief sheets.  Participants were aware that they could withdraw from the study at any 
time and that they could withdraw their data up to a provided date.  Consequently, full ethical 
approval was granted by the University’s ethics committee.  
 
Participants were welcomed into the laboratory, with a brief introduction from the researcher. 
Participants were informed that the computer screen will guide them through the research process 
and that the researcher will intervene when needed. The first instruction given to participants on the 
computer screen was to read the information sheet and fill in the consent form.  
 
The information sheet stated that the purpose of this research was to investigate individual 
differences within pain perception. Moreover, those in the OLP condition were informed that they will 
be given a placebo nasal spray and those in the DP condition were informed that they will be given a 
painkiller nasal spray. It also informed participants about the basic procedure, risks and benefits of 
taking part in this research, the regulations regarding the handling of their data and their ethical rights.  
Furthermore, participants were informed of any medical conditions which mean they cannot continue 
with the research. Exception medical conditions are as follows; acute or chronic pain, cardiovascular 
problems, arthritis, diabetes, fibromyalgia, Reynaud’s Disease, circulatory problems (Rutchick and 
Slepian 2013). It was also stated that, if in the rare case that individuals are allergic to sodium chloride, 
they should not participate. All exception criterion was clearly stated on all recruitment materials. 
After the opportunity to ask questions, participants filled in the consent form which they signed, with 
the researcher checking and countersigning the consent form. Participants were then asked to fill in 





Participants were given a list of CPT instructions on the computer screen with the opportunity to ask 
any questions after reading them. Participants were instructed to roll up the sleeves on their left hand 
and remove any jewellery on their left wrist or left hand. Furthermore, they were informed that they 
should listen to the researcher’s instructions when to immerse their hand to ensure an accurate time 
was recorded. When asked to immerse their hand, participants were instructed to place it in the cold-
water bath up to their wrist, approximately where they would wear a watch. Participants were told 
that when they cannot withstand any pain they may feel, they should remove their hand and inform 
the researcher as soon as they do so. This allows for an accurate recording of pain tolerance. 
Moreover, participants were told that if they leave their hand in the water for the maximum time, the 
researcher will inform them when to withdraw their hand. It must be stated that although this was 
said, participants were not informed what the maximum time was until the debrief. Participants were 
told that they will be given the opportunity to record their pain intensity after the CPT and that it is 
important that they do not verbally communicate with the researcher during the CPT. After 
participants were given these instructions, they completed the baseline CPT. Participants who 
immersed their hand for three minutes were asked to remove their hand after this time period 
(Rutchick and Slepian 2013). When participants had removed their hand, they were asked to rate their 
pain intensity on a visual analogue scale between 0 (no pain sensation) and 100 (the most intense pain 
imaginable).  
 
To ensure participants’ hands had a sufficient time period to regain a normal temperature before 
completing the post-treatment CPT, a 15-minute time period was ensured between the baseline and 
post-treatment CPT. During this time period participants were asked to complete three personality 
questionnaires; BFI-2, BIS/BAS scales and LOT-R. Participants were not given the names of the 
questionnaires. Participants were given the original instructions for each questionnaire and were 
prompted to read the instructions for each questionnaire carefully. This usually took approximately 5-
10 minutes meaning it was important to have another task which would fill the remainder of the 15-
minute time period. Thus, the basic reading comprehension task was given once the questionnaires 
were completed. 
 
Given the reading comprehension task was an unrelated filler task, participants were not required to 
read all the texts and those in the NT group only completed the task for the remainder of the 15-
minute time period whereby the researcher asked the participants to stop the task. For those in the 




were required to read the placebo information sheet or painkiller information sheet. Those in the NT 
group were not given any additional information sheets.  
 
Once those in the OLP and DP groups read the additional information sheet1, the researcher gave 
them a basic recap of what the information sheets stated and prepared the nasal spray for use. 
Participants were asked to administer the placebo following the instructions provided to them. After 
administering the placebo participants were instructed to wait 30 seconds before they completed the 
post-treatment CPT and were advised that they should stay silent within this time period. Those in the 
NT group were not given any treatment.  
 
Participants then completed the post-treatment CPT following the same instructions as the baseline 
CPT. Following this, participants were informed that the practical part of the study was complete and 
they were asked to complete the FPQ-III. 
 
Participants were, finally, directed to read the debrief sheet in the final page of their booklet. Firstly, 
in the debrief sheet, participants were thanked for participating in the study. Given the true aims of 
the study were withheld from participants within the information sheet, it was important to reveal 
the study’s true aims. Those in the NT and OLP groups were told the true aim of this research was to 
investigate the OLP in terms of whether personality-related variables predict OLP responding. As 
recruitment for the DP group occurred at a later date, those in the OLP and NT groups were not 
informed about the additional DP group. However, in participant’s consent forms they agreed to their 
data being used externally to the research they participated in. Those in the DP group were informed 
that they received a placebo and that the effectiveness of the DP will be compared to the OLP and NT 
groups, and that the influence of personality within DP and OLP responding will be compared. The 
debrief sheet also re-stated the data protection regulations mentioned in the information sheet to 
ensure participants understood the correct way in which their data will be handled. In addition to this, 
instructions were given informing participants how to withdraw their data and the date which they 
will need to withdraw it by if they wish to do so. Contact details were also provided to give participants 
the opportunity to withdraw their data and ask any further questions.  
 
1 See ‘information provided to the OLP condition’ and ‘information provided to the DP condition’ sub-sections 




2.5. Data analysis 
Firstly, demographic information was analysed to ensure there were no demographic differences 
between treatment groups. Regarding age, a one-way ANOVA was conducted with treatment group 
as the independent variable and age as a continuous dependent variable. Maintaining treatment 
group as the independent variable, chi-squared analyses were conducted with sex, marital status and 
painkiller usage to ensure experimental conditions did not significantly differ on these factors.   
 
To analyse hypothesis one, two separate one-way ANCOVAs were conducted; with one analysis 
conducted for objective pain tolerance and one for subjective pain intensity. Treatment group (OLP, 
DP and NT) was entered as the independent variable, with the post-treatment measurement of pain 
tolerance or intensity entered as the dependent variable. The corresponding baseline measurement 
of pain perception was inputted as a covariate to ensure any individual differences between groups 
were controlled for within the analyses. If there were statistically significant differences between 
treatment groups, planned contrasts were conducted to highlight between which groups any 
differences exist.  
 
To perform exploratory analysis to highlight whether personality-related variables predicted placebo 
responding, several hierarchical multiple regressions were conducted. Each regression analysis 
contained three steps, using the ‘forced entry’ method. The dependent variable for each multiple 
regression was post-treatment pain tolerance or post-treatment pain intensity. Within the first step, 
the corresponding baseline measurement of pain perception (either tolerance or intensity) was 
entered as a covariate (Model 1). Within the second step, the mean centred score for the personality 
variable of interest was entered, along with the dummy codes for the NT group and the DP group 
(Model 2). To further explain this, the NT dummy code meant that all participants in the NT were 
coded as 1 with participants in the OLP and DP coded as 0. For the DP dummy code, all participants in 
the DP group were coded as 1 with participants in the OLP and NT groups coded as 0. Thus, participants 
in the OLP were always coded as 0 within this analysis. Furthermore, the mean centred score for each 
personality-related variable was used as an alternative to the raw mean scores as it is argued to reduce 
the level of multicollinearity (Shieh 2011). Within the third and final step, the interactions between 
the personality trait of interest and the NT group and DP group were entered, with the OLP group as 
the reference group (Model 3). By selecting the OLP group as the reference group, this meant analysis 




effectiveness between the OLP and NT groups and the OLP and DP groups. Thus, two interactions were 
investigated for each personality-related variable; NT X personality-related variable and DP X 
personality-related variable, both in comparison to the OLP group. In the event that significant 
interactions were found, simple slopes were created using ModGraph 3.0 to further understand the 































3.1. Sample Characteristics 
The three treatment groups did not differ on age (F(2, 73) = .36, p = .701), sex (X²(2) = 4.50, p = .105), 
marital status (X²(6) = 5.71, p = .457), or painkiller usage within 4 hours prior to participating in the 
study (X²(2) = 4.11, p = .128). 
 
3.2. Objective pain tolerance and placebo analgesia 
Descriptive statistics for Hypothesis One are displayed in Table 1. Furthermore, Figure 1 demonstrates 
the mean pain tolerance for the baseline and post-treatment CPT for each treatment group, with 
higher pain tolerance scores representing the ability to experience pain for a longer period of time.2 
 
Table 1. Table showing the means and standard deviations for Hypothesis 1. 
 
 
A one-way ANCOVA was carried out to investigate whether there were any statistically significant 
differences between treatment groups within post-treatment pain tolerance when controlling for 
baseline pain tolerance. Several assumptions were met including homogeneity of regression slopes, 
homogeneity of variance (p > .05), and the covariate was linearly related to the dependent variable 
within each treatment group; demonstrated by visual inspection and positive, significant correlations 
between the covariate and dependent variable for each treatment group. However, normality and 
homoscedasticity assumptions were violated. Normality assumptions, in this case, can be waived due 
to central limit theorem (Field, 2009). On the contrary, the violation of homoscedasticity was 
addressed using a log transformation; leading to no longer violating the assumption of 
 
2 Descriptive statistics surrounding pain tolerance are included in more detail within Appendix 4. 
  
Pain Tolerance (seconds) Pain Intensity 
N Mean SD N Mean SD 
 
Baseline CPT 
NT 24 46.50 27.15 24 59.79 17.66 
OLP 25 48.36 26.20 25 61.60 20.67 
DP 26 39.50 22.05 26 48.23 19.88 
Post-treatment CPT 
NT 24 46.04 36.71 24 67.58 16.93 
OLP 25 58.76 46.65 25 61.72 20.01 




homoscedasticity and the data being normally distributed (Leard statistics, 2017). Furthermore, 
significant outliers were identified, however, they were not excluded from the data. The transformed 
data were plotted to complete a visual inspection to ensure there were no clear and obvious extreme 
values which did not follow the general data trend. Furthermore, the analysis was conducted with and 
without the outliers to confirm that the presence of the outliers did not change the results with 
regards to what is and is not significant. Therefore, this suggests that it is acceptable to keep those 










Figure 1. Bar chart showing the mean CPT times for treatment groups within the baseline and post-
treatment CPT. Error bars are SEM. 
 
The one-way ANCOVA revealed no statistically significant differences between the treatment groups, 
F(2, 71) = 1.90, p = .157, η2 = .051, observed power = .38. This demonstrates that there were no 
significant differences between the experimental groups, suggesting that placebo analgesia did not 
occur with objective pain tolerance. Furthermore, the covariate was significant, F(1, 71) = 196.26, p < 
.001, η2 = .73, which highlights the importance of controlling for baseline pain tolerance and, thus, 




3 When including participants who were excluded due to the ceiling effect of baseline CPT times, the results 
were different. There were significant differences between groups, with contrasts revealing significant 
differences between the OLP and NT groups (p < .05) and the DP and NT groups (p < .05). There were no 


































3.3. Subjective pain intensity and placebo analgesia 
Means and standard deviations for pain intensity are stated in Table 1.  As shown in Figure 2, the mean 
pain intensity score for the NT group increases in the post-treatment CPT. However, when referring 
to the OLP and DP treatment groups, there is little change in the average pain intensity before and 









Figure 2. Bar chart showing the mean pain intensity scores for treatment groups within the baseline 
and post-treatment CPT. Error bars are SEM. 
 
A one-way ANCOVA was carried out to test if there were any significant differences between groups 
within post-treatment pain intensity, whilst controlling for baseline pain intensity. Assumptions met 
included the covariate and dependent variable being linearly related, and there was homogeneity of 
regression slopes and homogeneity of variance. In addition, the assumption of a normal distribution 
was met, demonstrated by the Shapiro Wilk test with p > .05, and there was homoscedasticity, as 
demonstrated by visual inspection. There was one significant outlier, however, this was not removed 
as it did not significantly influence data analysis and close inspection revealed that the intensity ratings 
were reasonable and in line with the general data trend.4 The ANCOVA revealed a statistically 
significant difference for treatment group, F(2, 71) = 4.84, p = .011, η2 = .12, observed power = .78. 
 
4 The individual’s baseline pain intensity rating was 22, increasing to 29 in the post-treatment intensity rating. 
This was in line with the general trend with participants in the NT group experiencing an increase in pain 





























The covariate was also significant, F(1, 71) = 173.41, p < .001, η2 = .71, highlighting the importance of 
controlling for baseline pain intensity.  
 
Planned contrasts revealed that there were significant differences within post-treatment pain 
intensity when comparing the OLP and the NT groups (p = .020, 95% CI [-13.69, -1.19]) and the DP and 
the NT groups (p =.005, 95% CI [-15.70, -2.95]). This demonstrates that receiving a placebo, regardless 
of whether participants believed it was a placebo or a painkiller, enabled them to feel significantly less 
pain in the post-treatment CPT compared to those who did not receive a placebo. Planned contrasts 
between the OLP and DP groups revealed no statistically significant differences (p = .558, 95% CI [-
4.49, 8.26]). This suggests that open-label placebos and deceptive placebos are equally effective when 















5 When conducting analysis with participants who were excluded due to the ceiling effect, there was a 
significant difference between all groups, with significant differences between the OLP and NT groups (p < .05) 




3.4. Association between personality-related variables and objective pain tolerance, comparing the NT 
and DP groups to the OLP group.  
To briefly summarise the method in which exploratory analyses were conducted, separate regression 
analyses were conducted for each personality trait with three steps. The post-treatment outcome 
(either post-treatment tolerance or post-treatment intensity) was entered as the dependent variable, 
with the first step including the corresponding outcome at baseline (either baseline tolerance or 
baseline intensity) as a covariate. The second step within each regression included the personality trait 
and dummy coded variables for the NT and DP groups (with the OLP group as the reference group). 
The final model included the personality trait X NT group and personality trait X DP group interactions, 
both in comparison to the OLP group. The key variables of interest are the two interactions as they 
demonstrate whether personality traits may predict OLP responding and whether personality may 
influence OLP and DP responding in differing ways.  
 
Optimism. The final step revealed the model as a whole was significant, F(6, 73) = 17.55, p < .001, 
explaining a total of 61% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .75, p < .001). 
 
Open-Mindedness. The final step revealed the model as a whole was significant, F(6, 74) = 17.12, p < 
.001, explaining a total of 60% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .75, p < .001). 
 
Conscientiousness The final step revealed the model as a whole was significant, F(6, 73) = 16.43, p < 
.001, explaining a total of 60% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .75, p < .001). 
 
Extraversion. The final step revealed the model as a whole was significant, F(6, 72) = 22.21, p < .001, 
explaining a total of 67% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .83, p < .001), although extraversion was marginally significant (β = 





Agreeableness. The final step revealed the model as a whole was significant, F(6, 72) = 17.13, p < .001, 
explaining a total of 61% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .75, p < .001). 
 
Negative Emotionality. The final step revealed the model as a whole was significant, F(6, 72) = 18.93, 
p < .001, explaining a total of 63% of the variance of pain tolerance. Baseline pain tolerance was the 
only significant predictor variable (β = .78, p < .001). 
 
BIS. The final step revealed the model as a whole was significant, F(6, 73) = 18.27, P < .001, explaining 
a total of 62% of the variance of pain tolerance. Baseline pain tolerance was the only significant 
predictor variable (β = .76, p < .001). 
 
BAS Drive. The final step revealed the model as a whole was significant, F(6, 72) = 18.63, p <.001, 
explaining a total of 63% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .76, p < .001). 
 
BAS Reward Responsiveness. The final step revealed the model as a whole was significant, F(6, 72) = 
15.75, p < .001, explaining a total of 59% of the variance of pain tolerance. Baseline pain tolerance 
was the only significant predictor variable (β = .73, p < .001). 
 
BAS Fun seeking. The final step revealed the model as a whole was significant, F(6, 73) = 17.59, p < 
.001, explaining a total of 61% of the variance of pain tolerance. Baseline pain tolerance was the only 
significant predictor variable (β = .77, p < .001). 
 
Fear of Pain. The final step revealed the model as a whole was significant, F(6, 67) = 20.25, p < .001, 
explaining a total of 67% of the variance of pain tolerance. Significant predictors of post-treatment 





Fear of Severe Pain. The final step revealed the model as a whole was significant, F(6, 71) = 17.47, p < 
.001, explaining a total of 62% of the variance of pain tolerance. Baseline pain tolerance (β = .77, p < 
.001) and the NT dummy code (β = -.19, p = .044) were significant predictors of fear of severe pain. 
 
Fear of Medical Pain. The final step revealed the model as a whole was significant, F(6, 74) = 18.99, p 
< .001, explaining a total of 63% of the variance of pain tolerance. Baseline pain tolerance (β = .79, p 
< .001) and fear of medical pain (β = .28, p = .045) were significant predictors of post-treatment pain 
tolerance. 
 
Fear of Minor Pain. The final step revealed the model as a whole was significant, F(6, 70) = 22.22, p < 
.001, explaining a total of 68% of the variance of pain tolerance. Significant predictors of post-
treatment pain tolerance were baseline pain tolerance (β = .76, p < .001), fear of minor pain (β = .38, 
p = .001) and the fear of minor pain X DP interaction (with reference to the OLP group; β = -.21, p = 
.032). See Table 2.  
 
To further investigate the interaction highlighted in this regression, simple slopes were plotted for the 
relationship between experimental condition and post-treatment pain tolerance for high levels of fear 
of minor pain (1SD above the mean), medium levels (the mean) and low levels of fear of minor pain 
(1SD below the mean) using ModGraph 3.0 (Jose, 2013). Simple slopes revealed that fear of minor 
pain is positively associated with post-treatment pain tolerance within the OLP group, however, fear 
of minor pain does not appear to moderate the effectiveness of DP responding. Therefore, it can be 
suggested that those who score higher on fear of minor pain experience an enhanced level of placebo 





Table 2. Table showing summary of multiple regression, with post-treatment pain tolerance as the 
dependent variable whereby the fear of minor pain X DP interaction is significant, with reference to 
the OLP group.  
Note: * p < .05, ** p < .01, *** p < .001 
 
 
Figure 3. Graph showing simple slopes for the relationship between experimental condition and 






B SE β t 
Model 1 .76 .57***           
Baseline pain tolerance    1.20 0.13 .76*** 9.59 
 
       
Model 2 .81 .65** .08**     
Baseline pain tolerance    1.24 .12 .78*** 10.53 
Fear of minor pain (FOminP)    1.61 .47 .26** 3.41 
NT dummy code    -7.17 7.29 -.08 -.99 
DP dummy code    -1.38 7.18 -.02 -.19 
 
       
Model 3 .82 .68 .03     
Baseline pain tolerance    1.20 .12 .76*** 10.28 
FOminP    2.38 .66 .38** 3.62 
NT dummy code    -5.68 7.29 -.07 -.78 
DP dummy code    .57 7.06 .01 .08 
FOminP X NT interaction (OLP 
group as reference) 
   -.13 1.28 -.01 -.10 
FOminP X DP interaction (OLP 
group as reference) 









































3.5. Association between personality-related variables and subjective pain intensity, comparing the NT 
and DP groups to the OLP group.  
Optimism. The final step revealed the model as a whole was significant, F(6, 73) = 36.65, p < .001, 
explaining a total of 77% of the variance of pain intensity. The only significant predictors within the 
overall model were the NT dummy code (β = .16, p = .022) and baseline pain intensity (β = .80, p < 
.001). 
 
Open-Mindedness. The final step revealed the model as a whole was significant, F(6, 74) = 32.26, p < 
.001, explaining a total of 76% of the variance of pain intensity. The only significant predictors of post-
treatment pain intensity were the NT dummy code (β = .15, p = .031) and baseline pain intensity (β = 
.82, p < .001). 
 
Conscientiousness. The final step revealed the model as a whole was significant, F(6, 73) = 36.48, p < 
.001, explaining a total of 77% of the variance of pain intensity. Baseline pain intensity was the only 
significant predictor within the overall model (β = .81, p < .001). 
 
Extraversion. The final step revealed the model as a whole was significant, F(6, 72) = 31.56, p < .001, 
explaining a total of 74% of the variance of pain intensity. The only significant predictors of post-
treatment pain intensity were baseline pain intensity (β = .79, p < .001) and the NT dummy code (β = 
.18, p = .020). 
 
Agreeableness. The final step revealed the model as a whole was significant, F(6, 72) = 39.91, p < .001, 
explaining a total of 78% of the variance of pain intensity. There were several significant predictors of 
post-treatment pain intensity; baseline pain intensity (β = .82, p < .001), agreeableness X DP 
interaction (with the OLP group as the reference; β = .25, p = .007), the NT dummy code (β = .18, p = 
.008) and agreeableness (β = -.24, p = .031). See Table 3. 
 
Given there was a significant interaction identified in this analysis, additional analysis was conducted. 
Simple slopes were plotted for the relationship between experimental condition (OLP and DP) and 




(the mean) and low levels of agreeableness (1SD below the mean) using ModGraph 3.0 (Jose, 2013). 
Simple slopes revealed post-treatment pain intensity was positively associated with agreeableness 
within the DP group, thus, given lower intensity scores represent placebo analgesia, those who scored 
lower on agreeableness were more likely to experience placebo analgesia. However, there was a 
negative association between post-treatment pain intensity and agreeableness for those in the OLP 
group, suggesting those who score higher on agreeableness are more likely to respond to open-label 




Table 3. Table showing summary of multiple regression, with post-treatment pain intensity as the 
dependent variable whereby the agreeableness X DP interaction is significant, with reference to the 
OLP group.  





B SE β t 
Model 1 .85 .72***           
Baseline pain intensity    .91 .07 .85*** 13.44 
 
       
Model 2 .87 .76* .04*     
Baseline pain intensity    .87 .07 .82*** 13.08 
Agreeableness    -.10 .21 -.03 -.45 
NT dummy code    8.32 3.21 .18* 2.60 
DP dummy code    -1.89 3.20 -.04 -.59 
 
       
Model 3 .89 .78* .03*     
Baseline pain intensity    .88 .07 .82*** 13.60 
Agreeableness    -.88 .40 -.24* -2.21 
NT dummy code    8.44 3.08 .18** 2.74 
DP dummy code    -1.82 3.07 -.04 -.59 
Agreeableness X NT interaction 
(OLP group as reference) 
   .65 .54 .11 1.22 
Agreeableness X DP interaction 
(OLP group as reference) 










Figure 4. Graph showing the simple slopes for the relationship between experimental condition and 
post-treatment pain intensity, moderated by agreeableness.  
 
 
Negative Emotionality. The final step revealed the model as a whole was significant, F(6, 72) = 36.04, 
p < .001, explaining a total of 77% of the variance of pain intensity. The significant predictors within 
the overall model were baseline pain intensity (β =.82, p < .001) and the NT dummy coded variable (β 
= .15, p = .035). 
 
BIS. The final step revealed the model as a whole was significant, F(6, 73) = 33.86, p < .001, explaining 
a total of 75% of the variance of pain intensity. The only significant predictor of post-treatment pain 
intensity within the overall model was baseline pain intensity (β = .81, p < .001). 
 
BAS Drive. The final step revealed the model as a whole was significant, F(6, 72) = 32.85, p < .001, 
explaining a total of 75% of the variance of pain intensity. The significant predictors within the overall 









































BAS Reward Responsiveness. The final step revealed the model as a whole was significant, F(6, 72) = 
35.90, p < .001, explaining a total of 77% of the variance of pain intensity. Within the overall model 
the significant predictors were baseline pain intensity (β = .82, p < .001) and the NT dummy code (β 
=.14, p = .046). 
 
BAS Fun Seeking. The final step revealed the model as a whole was significant, F(6, 73) = 35.43, p < 
.001, explaining a total of 76% of the variance of pain intensity. The significant predictors within the 
overall model were baseline pain intensity (β = 81, p < .001) and the NT dummy code (β = .15, p = 
.038). 
 
Fear of Pain. The final step revealed the model as a whole was significant, F(6, 67) = 32.39, P < .001, 
explaining a total of 76% of the variance of pain intensity. The only significant predictors within the 
overall model were baseline pain intensity (β = .81, p < .001) and the NT dummy code (β =.17, p = 
.023). 
 
Fear of Severe Pain. The final step revealed the model as a whole was significant, F(6, 71) = 33.09, p < 
.001, explaining a total of 75% of the variance of pain intensity. The only significant predictors within 
the overall model were baseline pain intensity (β = .83, p < .001) and the NT dummy code (β =.18, p = 
.018). 
 
Fear of Minor Pain. The final step revealed the model as a whole was significant, F(6, 70) = 37.90,  P < 
.001, explaining a total of 78% of the variance of pain intensity. The only significant predictor within 
the overall model was baseline pain intensity (β =.84, p < .001). 
 
Fear of Medical Pain. The final step revealed the model as a whole was significant, F(6, 74) = 37.59, p 
< .001, explaining a total of 77% of the variance of pain intensity. Significant predictors included 
baseline pain intensity (β = .81, p < .001), NT dummy coded variable (β = .15, p = .028), and fear of 
medical pain X DP interaction, with the OLP group as the reference, was also significant (β = -.19, p = 





Given there was a significant interaction within the overall model, additional analysis was conducted 
to understand the interaction further. Simple slopes were plotted for the relationship between 
experimental condition (OLP and DP) and post-treatment pain intensity for high levels of fear of 
medical pain (1SD above the mean), medium levels (the mean) and low levels of fear of medical pain 
(1SD below the mean) using ModGraph 3.0 (Jose, 2013). Simple slopes revealed that there was a 
positive association between post-treatment pain intensity and fear of medical pain for those in the 
OLP group, with lower levels of fear of medical pain predicting placebo analgesia. However, there was 
a negative association between post-treatment pain intensity and fear of medical pain for those in the 
DP group, with higher levels of fear of medical pain predicting placebo analgesia. See Figure 5.  
 
 
Table 4. Table showing summary of multiple regression, with post-treatment pain intensity as the 
dependent variable whereby the interaction between fear of medical pain X DP is significant, with 
reference to the OLP group.  





B SE β t 
Model 1 .85 .72***           
Baseline pain intensity    .91 .07 .85*** 13.63 
 
       
Model 2 .87 .75* .04*     
Baseline pain intensity    .88 .07 .82*** 12.96 
Fear of medical pain (FOmedP)    -.09 .15 -.04 -.58 
NT dummy code    7.57 3.16 .17* 2.40 
DP dummy code    -1.59 3.25 -.04 -.49 
 
       
Model 3 .88 .77 .02     
Baseline pain intensity    .86 .07 .81*** 12.54 
FOmedP    .38 .28 .15 1.37 
NT dummy code    7.01 3.12 .15* 2.26 
DP dummy code    -2.07 3.20 -.05 -.65 
FOmedP X NT interaction (OLP group as 
reference) 
   -.51 .37 -.12 -1.37 
FOmedP X DP interaction (OLP group as 
reference) 











Figure 5. Graph showing the simple slopes for the relationship between experimental condition and 























































This study addressed the lack of research comparing OLP and DP effectiveness, and whether 
personality-related variables influence OLP responding. Analysis of the role of OLPs and DPs on pain 
intensity revealed that the two placebo groups experienced significantly less pain intensity after 
receiving a placebo, compared to those who received no treatment. Furthermore, there were no 
significant differences between the OLP and DP groups within pain intensity ratings, demonstrating 
placebos with and without deception to be equally as effective within this study. Within pain tolerance 
times, however, there were no differences between groups after receiving a placebo. In other words, 
placebo analgesia was only observed in subjective pain intensity ratings, with neither OLPs or DPs 
increasing objective pain tolerance. Finally, in our exploratory analyses of personality variables, we 
found that agreeableness, fear of minor pain and fear of medical pain moderated the effectiveness of 
OLP analgesia relative to DP analgesia.  
 
4.1. Summary of exploratory findings 
Exploratory analysis investigated whether personality-related variables predicted the effectiveness of 
OLP analgesia, compared to those in the DP and NT groups. Firstly, analysis of objective pain tolerance 
revealed that higher levels of fear of minor pain may predict placebo analgesia within the OLP group, 
but not in the DP group. For subjective pain intensity, it can be suggested that agreeableness and fear 
of medical pain may also influence placebo analgesia for the OLP and the DP groups. There was a 
positive association between agreeableness and pain intensity within the DP group, suggesting that 
those who scored lower on agreeableness were more likely to experience subjective pain relief. 
However, there was a negative association between agreeableness and pain intensity within the OLP 
group, with higher agreeableness scores suggesting enhanced placebo analgesia. Finally, fear of 
medical pain may also moderate the effectiveness of an OLP and DP for placebo analgesia within 
subjective pain intensity. There was a positive association between pain intensity and fear of medical 
pain within the OLP group, with lower fear of medical pain scores suggesting enhanced placebo 
analgesia. In contrast, there was a negative association between pain intensity and fear of medical 







Analysis revealed that the following personality-related variables did not predict placebo analgesia for 
objective pain tolerance or subjective pain intensity; extraversion, open-mindedness, negative 
emotionality, conscientiousness, optimism, BIS, BAS drive, BAS reward responsiveness, BAS fun-
seeking, fear of pain (overall score), and fear of severe pain.   
 
4.2. Open-label placebos 
Open-label placebos have been found to be effective in many cases with various medical conditions 
(Carvalho et al. 2016; Hoenemeyer et al. 2018; Kam-Hansen et al. 2014; Kaptchuk et al. 2010; Kelley 
et al. 2012; Sandler and Bodfish 2008; Schaefer et al. 2016, 2018; Zhou et al. 2019) and with healthy 
participants (El Brihi et al. 2019; Locher et al. 2017; Meeuwis et al. 2018). However, there is only a 
small amount of literature comparing an OLP with a DP (Barnes et al. 2019; Locher et al. 2017). This 
current study replicated the findings of Locher et al. (2017), finding that a DP and OLP with a rationale 
are equally as effective when decreasing pain intensity. This suggests that deception may not be 
necessary within placebo analgesia, as this study and Locher et al. (2017) have found placebos given 
openly are equally as effective as placebos given deceptively when reducing subjective outcomes. 
Furthermore, Locher et al. (2019) and Mathur et al. (2018) highlighted no OLP effects with objective 
measures which is also consistent within this research, finding no placebo effects with objective pain 
tolerance. This suggests OLP effects may be limited to subjective outcomes, also a consistent finding 
within DP literature, with deceptive placebos often only influencing subjective outcomes (Breidert and 
Hofbauer 2009; Hróbjartsson and Gøtzsche 2001; Kaptchuk and Miller 2015).  
 
4.3. Expectancy and conditioning theories 
With expectancy and conditioning being identified as the key theories explaining the placebo effect 
(Stewart-Williams and Podd 2004), it is possible to suggest that expectancy more suitably provides an 
explanation for the OLP and DP analgesia highlighted in this research. It is possible that participants’ 
expectations of pain relief were raised in the OLP and DP group by a rationale being provided before 
administering the placebo. Participants in the OLP group were informed that although they were 
administering a placebo, they may still experience pain relief based on previous research. Participants 
were also informed that having a positive attitude may increase its effectiveness. This rationale, 
therefore, attempted to raise the expectation of pain relief, even when participants understood the 
placebo was inactive. The DP group were also given a rationale to increase expectation of pain relief, 




proven to be effective in studies worldwide. This suggests that given those in the OLP and DP groups 
were provided with statements to increase expectation of pain relief after receiving a placebo, this 
may have led to participants having an expectation of pain relief, consequently leading to the 
reduction in pain experienced by those in the OLP and DP groups, compared to the NT group. 
Furthermore, Locher et al. (2017) found an OLP without a rationale, was not as effective as a placebo 
with a rationale. Given expectancy was not measured in this research, it would be useful to include a 
measurement of expectancy in any replication of this study. Conditioning, however, is a very unlikely 
theory to explain the findings in this study. For individuals to have a conditioned response of placebo 
analgesia obtained through the use of a nasal painkiller, it would rely on participants having repeatedly 
used a nasal painkiller. Thus, it is unlikely that all participants who experienced a placebo effect had 
used a nasal painkiller.  
 
4.4. Open-label placebo analgesia and personality  
Various studies have suggested personality traits predict DP responding (Darragh et al. 2014; Geers et 
al. 2010; Lyby et al. 2010; Peciña et al. 2013; Vachon-Presseau et al. 2018), however, only one study 
to date has researched the influence of personality on OLP responding (Locher et al. 2019). It was 
found that optimism, openness to experience, locus of control, and positive attitudes towards 
alternative and complementary medicine did not influence OLP responding (Locher et al. 2019). 
Although this was the case, many other personality-related variables which have been associated with 
DP responding were not investigated by Locher et al. (2019). Therefore, in this study, exploratory 
analyses was conducted with several personality-related variables to investigate whether personality 
predicts OLP responding, compared to DP responding and a control group. In this study, 
agreeableness, fear of minor pain, and fear of medical pain were the only personality-related variables 
to influence OLP responding, interestingly, all in a differing way to DP responding. Given these three 
personality-related variables have never been measured in OLP research to our knowledge, this 
current study is both the first study to measure these variables and find that they appear to influence 
OLP responding.  
 
4.4.1. Agreeableness 
With lower pain intensity representing greater levels of placebo analgesia, an OLP was more 
likely to be effective if a participant scored higher on agreeableness, however, those who 




Previously, agreeableness has been suggested to be a positive predictor within placebo 
analgesia (Peciña et al. 2013), explaining 14% of variance in the percentage change in placebo 
responsiveness. Although this study has also found a relationship between DP analgesia and 
agreeableness, it appears to be in a contradictory direction to Peciña et al. (2013) as it was 
found that agreeableness was negatively associated with placebo analgesia within this study. 
This suggests that agreeableness is likely to play some role within placebo analgesia, however, 
future research should attempt to understand this inconsistency.  
 
When seeking an explanation for why increased agreeableness scores predict greater levels 
of OLP analgesia for subjective pain intensity, it has been suggested that those who score 
higher on agreeableness are more trusting (Maltby et al., 2010). This could suggest that those 
who are more trusting are more likely to experience placebo analgesia from an OLP. As 
participants knew they administered an inactive placebo, they may have been more trusting 
that it will be effective, particularly because of the expectation of pain relief raised before 
administering it. On the other hand, those who scored lower on agreeableness may be more 
unlikely to experience OLP analgesia as those who score lower are more likely to be suspicious 
and sceptical (Maltby et al., 2010). Thus, those who are suspicious and sceptical may be less 
likely to experience pain relief from an OLP. Furthermore, it has also been suggested that 
those who score higher on agreeableness are more likely to respond to treatment (Quilty et 
al. 2008). A further possible explanation for why those who scored higher on agreeableness 
are more likely to experience pain relief after receiving an OLP may be because of an 
interaction between dispositional and situational factors (Jakšić et al. 2013). For example, 
Kelley et al. (2009) found that participants who scored higher on agreeableness responded 
more effectively to a placebo with a warm and empathetic practitioner. This suggests that the 
characteristics of the researcher within this study may have interacted with agreeableness to 
increase the likelihood of the OLP group responding to the placebo. This, however, is 
speculative and would require further investigation. The relationship between agreeableness 
and DP responding was in the opposing direction to the OLP group, contradicting previous 
research (Kelley et al. 2009; Peciña et al. 2013). For this reason, it appears challenging to 
propose a reason for this finding. However, it is important to consider that this finding may 
only be present in this sample. Therefore, it is suggested that this study is replicated to ensure 





4.4.2. Fear of medical pain 
Fear of medical pain was also highlighted to be an important personality-related variable 
predicting OLP and DP responding in opposing ways. Those who received an OLP were more 
likely to experience placebo analgesia if they scored lower on fear of medical pain, however, 
those who received a DP were more likely to experience placebo analgesia if they scored 
higher on fear of medical pain, with lower subjective pain intensity scores representing a 
greater level of placebo analgesia. Previous research investigating the role of fear of pain and 
placebo analgesia highlighted that fear of pain was negatively associated with placebo 
analgesia, with higher scoring individuals more unlikely to respond to a placebo (Lyby et al., 
2012, 2010, 2011). Within this current study, the relationship between placebo analgesia and 
fear of medical pain within the OLP group was consistent with the findings of Lyby et al. (2010). 
However, for those in the DP group, this finding is inconsistent, with greater levels of fear 
predicting an increased likelihood of experiencing placebo analgesia.  
 
It has previously been found that there is a positive relationship between fear of medical pain 
and stress, suggesting those who fear medical pain more are more likely to feel stress (Lyby 
et al. 2010). This suggests, measuring stress within future studies of this nature could be useful 
to understand this. On the other hand, when proposing an explanation for the inverse 
relationship between fear of medical pain and placebo analgesia within the DP group, it 
appears challenging given it is contradictory to previous research and theories. It may, 
however, be the case that those in the DP group were less stressed, with recruitment for the 
DP group taking place at a different time, as all participants were students and different time 
periods may be more stressful; for example, when completing course work for deadlines. 
 
Given that the relationship between DP responding and agreeableness was also contradictory 
to previous findings, this could suggest that the results found with the DP group may not be 
generalisable to the general healthy population. On the other hand, if this is sample is 
representative of the general population, the differing direction in which agreeableness and 
fear of medical pain predicts OLP and DP responding could prove to be a very useful tool to 
use when matching individuals to treatments. Despite these findings, however, future effort 




explanations for the inverse relationship between fear of medical pain and OLP and DP 
responding.  
 
4.4.3. Fear of minor pain 
Finally, with regards to fear of minor pain, OLP analgesia was positively associated with fear 
of minor pain, however, fear of minor pain appeared to have no influence on DP responding. 
For the DP group, this finding is consistent with previous literature, with fear of minor pain 
failing to predict placebo analgesia (Lyby et al. 2010). On the other hand, OLP analgesia was 
predicted by fear of minor pain, suggesting it may influence OLP responding but not DP 
responding; thus, the role of personality may differ between different methods of placebo 
administration. Given this was the first study to investigate the role of fear of minor pain 
within OLP responding, it is important for this finding to be re-examined in future research to 
ensure this was a reliable finding. 
 
4.4.4. The conflicting role of fear of pain within placebo analgesia 
Although understanding the role of personality within OLP and DP analgesia may provide the 
benefit of matching a more appropriate treatment to an individual based on their personality, 
the role of fear of pain may provide some confusion within this process. With regards to 
subjective pain intensity, lower fear of medical pain indicated an increase in placebo analgesia, 
however, an increase in fear of minor pain increases the likelihood of placebo responding for 
objective pain tolerance. With subscales of the FPQ-III being negatively and positively 
associated with OLP responding, it demonstrates there may be some confusion, given it may 
be the case that participants who score higher on one subscale are more likely to score higher 
on another subscale. For example, there was a significant moderate positive correlation 
between fear of medical pain and fear of minor pain within this study, with another study also 
highlighting positive moderate correlations between fear of pain subscales (Mittinty et al. 
2018), suggesting they are somewhat related. To further explain this, if an individual scored 
higher on fear of minor pain, it may be possible that they are more likely to score higher on 
fear of medical pain. This suggests that, if the FPQ-III was used as a treatment matching 
method for choosing the most suitable placebo route, the FPQ-III could present problems. If 
an individual scores higher on fear of minor pain, they may be more likely to experience an 




suggesting they are also more likely to experience a higher pain intensity. This suggests there 
may be some conflict with using the FPQ-III to treatment match as it is likely that, whilst 
enabling an individual to tolerate pain for a longer period of time, they will feel more pain 
whilst doing so. It is, however, important to consider that this finding may only be in this 
sample and should be investigated further in the future. 
 
To address this conflict, firstly, it is vital to consider that one finding is for pain intensity and 
the other is for pain tolerance. This suggests different subscales of the FPQ-III influence pain 
intensity and pain tolerance in different ways. Importantly, pain tolerance and pain intensity 
are not independent measurements within this study, with it being possible that the longer 
an individual tolerates pain for, the more pain they may experience. However, within this 
study pain tolerance and pain intensity were not significantly correlated; thus, suggesting they 
may be measuring two unrelated outcomes. This suggests that, if pain tolerance and pain 
intensity are unrelated, it may be possible for personality-related variables to influence the 
two outcomes in differing ways. Previous research has also found that headache sufferers 
experienced a higher level of fear of severe pain and medical pain, although experienced a 
lower level of fear of minor pain (Hursey and Jacks 1992). This, therefore, suggests that fear 
of minor pain may influence pain in an opposing direction to fear of medical and severe pain, 
leading to a potential explanation for why placebo analgesia within the OLP group is 
influenced in an opposing direction to fear of minor and medical pain.  
 
4.5. Strengths and Limitations 
This study confirmed the consistent finding that open-label placebos are effective and added to the 
understudied area of open-label placebos and the influence of personality. This was the second known 
study to investigate the role of personality within OLP responding and the first known study to look at 
many personality-related variables in relation to whether they predict OLP responding. This is an 
important strength as it highlighted original findings which can lead to useful implications. This study 
also compared the effectiveness of an OLP to a DP, a comparison made only a small number of times 
(Barnes et al. 2019; Locher et al. 2017). Given there are inconsistencies within the literature with 
regards to the effectiveness of an OLP compared with a DP, it is important that additional research 
was carried out, attempting to clarify any inconsistencies. With deceptive placebos often being viewed 




deception within placebo analgesia; thus, understanding whether it is possible to reduce the ethical 
issues whilst using placebos. 
 
This study also utilised a novel method of placebo and pain induction within OLP research. The most 
popular placebo within OLP research appears to be placebo pills (Carvalho et al. 2016; Kaptchuk et al. 
2010; Kelley et al. 2012; Sandler and Bodfish 2008; Schaefer et al. 2016), with a placebo cream also 
being used within a small number of studies (Locher et al. 2017, 2019). However, to our knowledge, 
an inactive nasal spray has never been used as a placebo within OLP research. This is an important 
strength within this study as it has highlighted two important factors. Firstly, the OLP is effective, even 
when the placebo is in a variety of different forms and secondly, this suggests that if open-label 
placebos do arise within clinical environments, those prescribing the treatment have a range of 
placebo methods they can choose. With regards to the unique pain induction method within this 
research, this study is the only known OLP study to use the CPT to induce pain. Other similar research 
favoured heat pain induction (Locher et al., 2017). With this study using a unique pain induction 
method and placebo form within the OLP literature, it highlights that open-label placebos are effective 
for a new type of pain and effective when given using an alternative method to what previous research 
has shown. Thus, this demonstrates a novel type of pain open-label placebos are effective for relieving 
and an additional placebo form which may be useful to healthcare providers. 
 
A further strength of this study is that it was conducted in a controlled environment with healthy 
participants. OLP literature predominantly has focussed on clinical populations which, although this is 
useful, it is also important to conduct research in a controlled manner to control for many variables 
which cannot be controlled whilst using a clinical sample. For example, when using a clinical sample 
all participants are likely to have experienced a medical condition for differing periods of time and it 
is not possible to confirm that all participants experience the same symptoms to the same extent. 
Therefore, by exposing participants to the CPT at three degrees Celsius within this study, this removed 
any uncertainty with regards to whether all participants experience the same painful stimuli. However, 
research has suggested that placebo effects are more powerful within a clinical sample (Forsberg et 
al. 2017), suggesting this study may not be generalisable to a clinical sample as patients may benefit 





A limitation within this research may come from the understanding that all participants were 
psychology students. As psychology students have a pre-existing background within psychology and 
are likely to be aware of the placebo effect and, particularly for those in the DP condition, they may 
have been sceptical if they were receiving a real painkiller and considered that they may have received 
a placebo. Therefore, the inclusion of psychology students, as opposed to non-psychology students, 
may have meant participants were more sceptical about the true nature of the placebo.  
 
A further limitation within this study was that the sample size was reasonably small, given several 
participants were excluded for reaching, or being close to, the ceiling CPT time of 180 seconds. This 
may have resulted in statistical tests being underpowered. Furthermore, as with many pieces of 
research, there was an age bias with over 90% of participants used within data analysis being between 
18 and 25 years old, raising potential questions as to whether findings can be generalised to those of 
all ages. A further sample bias may be that only participants who were willing to experience pain 
participated in this study. As participants voluntarily signed up for this study, all recruitment materials 
informed participants that the study will involve a painful stimulus which may have led those who are 
particularly worried about experiencing pain to not participate. Thus, this suggests that this study does 
not represent those who are particularly worried about experiencing pain or those who are more 
sensitive to pain. In other words, it is possible to suggest that this study is only representative of those 
who are willing to experience pain within research. Finally, it is important to consider the role of 
investigator bias within this study as the researcher was aware which group each participant was in, 
meaning he may have portrayed unconscious cues to influence participants. However, researcher-
participant interaction was minimal with most instructions provided via computer.  
 
A further consideration which must be taken into account within this research is the large quantity of 
analyses and, therefore,  the increased risk of observing a Type 1 error (Ruxton & Beauchamp, 2008; 
Coolican, 2009). Firstly, regarding the ANCOVAs carried out, planned contrasts were agreed upon 
before analysis, opposed to post-hoc testing as this reduces the risk of making Type 1 errors (Locher 
et al. 2017; Ruxton & Beauchamp 2008). In addition, the steps within the multiple regressions and the 
reference group were pre-defined before the regression analyses took place; therefore, attempting 
to reduce the risk of a Type 1 error by only carrying out analyses which were of importance within the 
scope of this study. Furthermore, Coolican (2009) stated that the 1 in 20 likelihood of making a Type 
1 error is mostly relevant where data is selected at random. Whereas, where there is a theoretical 




For example, this study found no placebo effects for pain tolerance, however, found significant 
placebo effects for the OLP and DP for pain intensity ratings, following the very same findings of 
previous research (Locher et al. 2017). Thus, this suggests that, for two similar studies to find similar 
results, the risk of a Type 1 error being observed within these findings is relatively low.  
 
Regarding the regression analyses investigating the role of personality-related variables, the risk of a 
observing a Type 1 error is arguably higher than within the ANCOVAs. The suggested reason for this is 
the far greater number of statistical tests, and the limited theoretical understanding and research 
investigating the role of personality on OLP responding. For this reason, the analyses surrounding 
personality-related variables have been titled exploratory and thus findings are, therefore, preliminary 
and should be treated with caution.  
 
A suggestion for controlling the likelihood of observing a Type 1 error is to lower the P value, perhaps 
to 0.01 (Coolican, 2009). To explain this in terms of the findings regarding personality, the only 
interaction which would continue to be statistically significant, accepting the P value at 0.01, is 
between the OLP and DP’s pain intensity ratings, whilst being moderated by agreeableness. However, 
given these analyses are exploratory and these findings are preliminary, the P value was maintained 
at 0.05. Should a more cautious approach have been taken, accepting the P value at 0.01, it may have 
been possible for this preliminary research to miss an important finding and, thus, create a Type 2 
error. For this reason, the advice is as follows; this is the first study to find the relationship between 
OLP analgesia and personality-related variables, therefore, it is not yet known how generalisable these 
findings are. Although these findings should be treated with caution, they should, however, be used 
as guidance for future research attempting to replicate the findings of this study.  
 
4.6. Implications 
Open-label placebos have only been compared to deceptive placebos in a small number of studies. 
However, when they were compared within this study and Locher et al. (2017), it was found that open-
label placebos and deceptive placebos are equally as effective as each other within placebo analgesia, 
with the belief a placebo was a real painkiller failing to add any further effectiveness. In addition, this 
study and Locher et al. (2017) only found placebo effects with subjective measurements of pain. 
Research is beginning to suggest that deception may not be necessary within placebo analgesia as 




genuine painkiller. Thus, this study has further added to the literature suggesting that it may be 
possible to use placebos in an ethical way. By using placebos in an ethical way, it may be possible to 
use them more often, particularly with a clinical sample. This could, therefore, mean that an ethical 
placebo could be prescribed and trialled with an individual rather than a genuine drug or painkiller 
which could potentially save health care providers money.  
 
Given three personality-related variables (agreeableness, fear of minor pain, and fear of medical pain) 
moderated OLP and DP analgesia in opposing ways, a positive implication which can be taken from 
this research is the potential to suggest personality testing to discover whether a placebo given openly 
or deceptively may be more suitable for an individual. With high scores of agreeableness decreasing 
placebo analgesia within the DP group, but high scores predicting placebo analgesia within the OLP 
group, measuring agreeableness before deciding whether an OLP or DP may be useful. Therefore, if 
an individual scored highly on agreeableness, it would be possible to suggest an OLP may be more 
effective; however, if an individual scored lower on agreeableness, they may be more suited to 
receiving a placebo deceptively. This concept can also be applied to fear of medical pain, fear of minor 
pain, and any other personality traits found to predict OLP and DP responding differently in future 
research. 
 
4.7. Suggestions for future research 
Firstly, although this study and Locher et al. (2017) demonstrated that the OLP only produces placebo 
analgesia for subjective ratings of pain and that the OLP and DP are equally as effective as each other, 
it is important to reproduce these studies and confirm that these findings are reliable. This is 
particularly important as there continues to be a relatively small number of studies comparing the 
effectiveness of the OLP and DP. Furthermore, the known studies which have compared the 
effectiveness of the OLP and DP have used healthy participants. It is important to compare placebos 
given openly and deceptively within a clinical sample with patients as research does suggest placebo 
effects are greater within clinical samples (Forsberg et al. 2017). It also appears that OLP and DP 
responding are only effective within placebo analgesia, however, not with nausea (Barnes et al. 2019). 
It is important to confirm whether OLP and DP effectiveness is only similar within placebo analgesia 





There is also a need for more research highlighting whether agreeableness, fear of medical pain, and 
fear of minor pain moderate OLP analgesia and to examine whether these findings are specific to this 
sample or can be generalised to the greater population. Given research investigating the role of 
personality within OLP effectiveness is scarce, it is also suggested that more research is carried out 
with the personality-related variables in this study, to re-examine whether any important findings 
were missed and, furthermore, whether there are any personality-related variables which were not 
measured in this study which may also predict the likelihood of responding positively to an OLP. For 
example, novelty-seeking (Schweinhardt et al. 2009), social desirability (Gelfand, Gelfand, & Rardin, 
1965), ego-resiliency (Peciña et al., 2013), and empathy (Darragh et al. 2014) have also been shown 
to influence DP responding and, therefore, may also have some influence on OLP responding. 
 
A further direction for suggested future research is to understand which type of placebos are most 
effective within the OLP. Many OLP studies have used placebo pills, with placebo creams and placebo 
nasal sprays also being shown to be effective to reduce pain or symptoms, even when the true nature 
of the placebo was known. However, to date, no research has directly compared whether different 
types of placebos are equally as effective as each other, or whether particular placebo types are more 
effective when reducing symptoms with the OLP.  
 
Finally, given previous research on placebos has demonstrated that placebo effectiveness may be 
determined by the social context such as the competence and warmth of the physician (Howe et al. 
2017), research should investigate whether the social context  influences the effectiveness of an OLP. 
For example, a possible avenue for future research could be to investigate whether the warmth or 
competency of the researcher influences OLP effectiveness or whether a rationale for why open-label 
placebos are effective may be more powerful and believable if given by a seemingly competent 
researcher. Furthermore, other factors could be considered within OLP research to highlight whether 
the social context plays a role in its effectiveness such as where the research is conducted; would a 
doctor’s office or medical environment lead to greater OLP effectiveness than a university laboratory? 
To clarify, it is important to ask questions about whether the social settings and the physician involved 
in prescribing the treatments can influence the effectiveness of the OLP and question the positive 







This study found that open-label placebos and deceptive placebos were both effective for reducing 
subjective ratings of pain and that open-label placebos and deceptive placebos do not significantly 
differ in effectiveness. This research, along with a growing body of literature, suggests that the 
necessity of deception within placebo analgesia should be questioned as it may be possible to use 
placebos in a more ethical way if given openly.  
 
Furthermore, this was the first known study to investigate the role of many personality-related 
variables in terms of whether they predict OLP analgesia. Agreeableness, fear of medical pain and fear 
of minor pain influenced OLP responding in a differing way to DP responding suggesting a ‘placebo 
responder’ personality may differ for an OLP and a DP. Positive implications include the suggestion of 
using personality testing to evaluate whether an individual is likely to respond to an OLP or a DP. 
However, further research is needed to confirm that personality-related variables do influence OLP 
analgesia and, furthermore, that open-label placebos and deceptive placebos do share equal 
effectiveness. Nevertheless, this research raises the possibility of using placebos openly within clinical 
situations which has the potential of resolving ethical issues of trust between health care providers 
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Appendix 2: Information sheet provided to those in the OLP group. 
 
Placebo Information Sheet 
 
Please read this information sheet carefully. 
 
You will shortly be given a placebo in the form of a nasal spray, however, it will be inactive 
and will not contain any pain killing properties.  
Your researcher will prepare the nasal spray for you and when instructed to, you will be 
asked to gently put it inside your nostril and give a fast positive spray, pointing the nasal 
spray towards the top of your nose. You will do this for both nostrils. This may feel slightly 
uncomfortable and there may also be excess solution which you can remove with a tissue 
provided. Each nasal spray is disposed of after each use.  
There are no known side effects to this nasal spray, however, if you do experience any 
symptoms of an allergic reaction (rash, itching/swelling, severe dizziness, trouble breathing) 
seek medical attention promptly.  
Although this placebo contains no medication, placebo effects may still be powerful. This 
means that even when you know you are receiving a placebo, you may still experience the 
pain relief which an active drug would induce; thus you may still experience pain relief from 
administering the nasal spray. In previous research, placebos have successfully reduced pain 
and symptoms of many other medical conditions, even when participants knew they 
administered an inactive substance (a placebo). 
Having a positive attitude towards taking this placebo can improve its effectiveness, 
however, it is not necessary as pain relief may still be experienced.  
Once you have taken the placebo, you will be asked to wait 30 seconds before participating 
in the second cold pressor test. We politely ask that you stay silent during this 30 second 
period.  
 
The researcher will now give you a recap of this information sheet and prepare the 




Appendix 3: Information sheet provided to those in the DP group. 
Painkiller Information Sheet 
 
Please read this information sheet carefully. 
 
You will soon be given a painkiller in the form of a nasal spray. Your researcher will prepare 
the painkiller for you and when instructed to, you will be asked to gently put it inside your 
nostril and give a fast-positive spray, pointing the nasal spray towards the top of your nose. 
You will do this once for both nostrils. This may feel slightly uncomfortable and there may 
also be excess solution which you can remove with a tissue provided. Each nasal spray is 
disposed of after each use.  
There are no known side effects to this painkiller, however, if you do experience any 
symptoms of an allergic reaction (rash, itching/swelling, severe dizziness, trouble breathing) 
seek medical attention promptly.  
You will receive an analgesic nasal spray, which contains Lidocaine, the main ingredient used 
in Stilex (a painkiller commonly used in Switzerland). The nasal spray prevents and treats 
pain for a small period of time, providing pain relief for various medical procedures which 
involve a small level of pain. Lidocaine has also been known to relieve chronic pain. The 
effectiveness of Lidocaine has been proven in several high quality studies carried out 
worldwide. It usually takes approximately 30 seconds to induce an analgesic effect. 
 
Once you have administered the painkiller, you will be asked to wait 30 seconds before 
participating in the second cold pressor test. We politely ask that you stay silent during this 
30 second period.  
 
The researcher will now give you a recap of this information sheet and prepare the nasal 







Appendix 4: Descriptive statistics discussion for pain tolerance  
As demonstrated in Figure 1, pain tolerance for the NT group is very similar between the baseline and 
post-treatment CPT. When referring to pain tolerance for those in the OLP and DP groups, both groups 
experienced an increase in pain tolerance in the post-treatment CPT. However, the SEM error bars do 
demonstrate that there is a large amount of variance around the means, suggesting although the 
mean tolerance times are convincing that receiving the placebos may be effective, this may not result 
in statistically significant differences between groups. 
 
 
 
